Undetectable equals untransmittable (U=U) has improved HIV prevention and tackled stigma, but there are still a few questions to answer.
A leading researcher at the Centers for Disease Control and Prevention addressed community concerns that surveillance data will be used to put people in prison under HIV criminalization laws.
'Drug Users Are People Too': Addressing Opioid Addiction, Chemsex, Alcoholism, and Smoking Among People Living With HIV
A CROI 2019 symposium demonstrated the need for continued research and programs that address substance use and its impact on people living with HIV.
"We don't need to spend another $140 million to find out how to retain people in care," activist David Barr writes. "We need to invest in the kinds of services people need so that they can use treatment easily and effectively."
The HIV-resistant gene mutation CCR5 delta 32 has an interesting past. Could it also be the future of HIV treatment and prevention?
Young adults, blacks, cisgender women, and people in rural areas, as well as people on Medicaid, were less likely to persist on PrEP.
People With HIV Have Substantially Higher Risk of Sudden Cardiac Death at Low CD4 Counts or Detectable Viral Load
New research involving veterans highlights the need to monitor HIV-positive patients for cardiovascular risk.
The global increase in sexually transmitted infections was a major focus of the CROI 2019 meeting in Seattle, Washington.
A CROI 2019 study suggests the dynamics of HIV proliferation in the viral reservoir might explain why viral load sometimes fails to become undetectable, especially when adherence is good.
Phase 3 Results With Dual Therapy Cabotegravir/Rilpivirine Long-Acting Injections: ATLAS and FLAIR Studies
Two oral presentations at CROI 2019 showed that dual therapy with long-acting monthly injections resulted in very low levels of virological failure with high participant preference for injections compared to oral combinations.